v3.26.3
Consolidated Statements of Earnings - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Revenues:        
Net earned premiums, principally supplemental health insurance [1] $ 3,304 $ 3,372 $ 9,866 $ 10,223
Net investment income 1,003 1,067 2,943 3,103
Net investment gains (losses) (1,072) 275 (1,176) (1,109)
Other income (loss) 36 26 101 81
Total revenues 3,271 4,740 11,734 12,298
Benefits and expenses:        
Benefits and claims, excluding reserve remeasurement 1,892 2,016 5,704 6,049
Reserve remeasurement (gains) losses (453) (580) (581) (658)
Total benefits and claims, net 1,439 1,436 5,123 5,391
Acquisition and operating expenses:        
Amortization of deferred policy acquisition costs 220 218 659 655
Insurance commissions 237 254 713 745
Insurance and other expenses 805 781 2,325 2,387
Interest expense 70 57 194 159
Total acquisition and operating expenses 1,332 1,310 3,891 3,946
Total benefits and expenses 2,771 2,746 9,014 9,337
Earnings before income taxes 500 1,994 2,720 2,961
Income taxes 197 355 573 694
Net earnings $ 303 $ 1,639 $ 2,147 $ 2,267
Net earnings per share:        
Basic (in dollars per share) $ 0.61 $ 3.09 $ 4.25 $ 4.22
Diluted (in dollars per share) $ 0.61 $ 3.08 $ 4.24 $ 4.21
Weighted-average outstanding common shares used in computing earnings per share (In thousands):        
Basic (in shares) 496,976 530,050 504,664 537,095
Diluted (in shares) 498,684 532,015 506,285 539,052
Cash dividends per share $ 0.61 $ 0.58 $ 1.83 $ 1.74
[1] Includes a gain (loss) of $52 and $(55) for the three-month periods and $52 and $(55) for the nine-month periods ended September 30, 2026 and 2025, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts.